MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

This study is testing a combination of two drugs — MIL62 (a monoclonal antibody similar to rituximab) and lenalidomide (an immune-boosting pill) — in people with certain types of slow-growing blood cancers (follicular lymphoma or marginal zone lymphoma) that have come back or stopped responding to previous treatment. **You may be eligible if...** - You are 18 years old or older - You have follicular lymphoma (grade 1, 2, or 3a) or marginal zone lymphoma confirmed by biopsy, and it is CD20-positive - Your cancer has progressed or not responded after at least one prior treatment - You are reasonably active (ECOG 0–2) - You have at least one measurable tumour - Your life expectancy is more than 6 months **You may NOT be eligible if...** - Your lymphoma is transforming into a more aggressive cancer - The cancer has spread to your brain - You have had radiation therapy in the past 42 days or chemotherapy in the past 28 days - You have had another cancer in the past 3 years (with some exceptions) - You are allergic to lenalidomide or thalidomide Talk to your doctor to see if this trial is right for you.